Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients

Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older DUBLIN, March 18, 2019 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN) today announced that the U.S. Food ... Biopharmaceuticals, FDA Allergan, AVYCAZ, ceftazidime, avibactam, cIAI , cUTI
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news